This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zaman Huri, H. Articles by Che Zuraini Sulaiman Search for Related Content Social Bookmarking                         What's this?

Use of Antiplatelet Agents for Primary and Secondary Prevention of Cardiovascular Disease Amongst Type 2 Diabetic Patients

Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, hasnizazh{at}um.edu.my

Lee Qiu Yi, BPharm

Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Rokiah Pendek, MBBCh, BAO, MRCP

Department Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Che Zuraini Sulaiman, BPharm, MClin Pharm

Pharmacy Unit, University Malaya Medical Centre, Selangor, Malaysia

Background. A retrospective observational study was conducted to study the use of antiplatelet agents for primary and secondary prevention of cardiovascular disease among hospitalized type 2 diabetes mellitus patients.

Method. A total of 355 patients were included in the study. The compliance with the American Diabetes Association recommendation on the use of antiplatelet therapy for prevention of cardiovascular disease was studied.

Results. For the primary prevention group, type 2 diabetes mellitus, patients with known dyslipidemia were more likely to receive antiplatelet therapy than those without dyslipidemia (P = 0.023). The rate of adherence to the American Diabetes Association recommendations on the use of antiplatelet therapy for secondary prevention of cardiovascular disease was higher than for primary prevention of cardiovascular disease (P = 0.001).

Conclusion. In conclusion, many of the eligible patients still do not receive antiplatelet therapy, particularly in primary prevention of cardiovascular disease. Measures should be taken to ensure that type 2 diabetes mellitus patients receive the antiplatelet therapy and hence prevent macrovascular complications.

Key Words: Type 2 diabetes • primary • secondary • prevention • cardiovascular disease • antiplatelet

Journal of Pharmacy Practice, Vol. 21, No. 4, 287-301 (2008)
DOI: 10.1177/0897190008318136


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?